UNH 2015.6.30 10-Q

 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________ 
Form 10-Q
__________________________________________________________ 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2015
or
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _______ TO _______
Commission file number: 1-10864
__________________________________________________________ 
    
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
 __________________________________________________________ 
Delaware
 
41-1321939
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
 
UnitedHealth Group Center
9900 Bren Road East
Minnetonka, Minnesota
 
55343
(Address of principal executive offices)
 
(Zip Code)
(952) 936-1300
(Registrant’s telephone number, including area code)
__________________________________________________________  
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer
x
 
Accelerated filer
o
 
Non-accelerated filer
o
 
Smaller reporting company
o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes o No x

As of July 24, 2015, there were 953,562,580 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.
 
 
 
 
 




UNITEDHEALTH GROUP
Table of Contents
 
 
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.
 
 
 
 
 
 
 














PART I
ITEM 1.    FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data)
 
June 30,
2015
 
December 31,
2014
Assets
 
 
 
 
Current assets:
 
 
 
 
Cash and cash equivalents
 
$
7,887

 
$
7,495

Short-term investments
 
1,915

 
1,741

Accounts receivable, net
 
6,034

 
4,252

Other current receivables, net
 
6,160

 
5,498

Assets under management
 
2,863

 
2,962

Deferred income taxes
 
514

 
556

Prepaid expenses and other current assets
 
2,193

 
1,052

Total current assets
 
27,566

 
23,556

Long-term investments
 
18,996

 
18,827

Property, equipment and capitalized software, net
 
4,473

 
4,418

Goodwill
 
34,154

 
32,940

Other intangible assets, net
 
3,316

 
3,669

Other assets
 
2,918

 
2,972

Total assets
 
$
91,423

 
$
86,382

Liabilities and shareholders’ equity
 
 
 
 
Current liabilities:
 
 
 
 
Medical costs payable
 
$
13,867

 
$
12,040

Accounts payable and accrued liabilities
 
10,901

 
9,247

Other policy liabilities
 
6,772

 
5,965

Commercial paper and current maturities of long-term debt
 
2,693

 
1,399

Unearned revenues
 
1,508

 
1,972

Total current liabilities
 
35,741

 
30,623

Long-term debt, less current maturities
 
15,378

 
16,007

Future policy benefits
 
2,491

 
2,488

Deferred income taxes
 
1,877

 
2,065

Other liabilities
 
1,301

 
1,357

Total liabilities
 
56,788

 
52,540

Commitments and contingencies (Note 10)
 
 
 


Redeemable noncontrolling interests
 
1,615

 
1,388

Shareholders’ equity:
 
 
 
 
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding
 

 

Common stock, $0.01 par value - 3,000 shares authorized;
952 and 954 issued and outstanding
 
10

 
10

Additional paid in capital
 
55

 

Retained earnings
 
35,262

 
33,836

Accumulated other comprehensive loss
 
(2,307
)
 
(1,392
)
Total shareholders’ equity
 
33,020

 
32,454

Total liabilities and shareholders’ equity
 
$
91,423

 
$
86,382

See Notes to the Condensed Consolidated Financial Statements

1

Table of Contents

UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
(in millions, except per share data)
 
2015
 
2014
 
2015
 
2014
Revenues:
 
 
 
 
 
 
 
 
Premiums
 
$
31,961

 
$
28,840

 
$
63,635

 
$
56,955

Services
 
2,865

 
2,447

 
5,571

 
4,851

Products
 
1,223

 
1,037

 
2,453

 
2,035

Investment and other income
 
214

 
250

 
360

 
441

Total revenues
 
36,263

 
32,574

 
72,019

 
64,282

Operating costs:
 
 
 
 
 
 
 
 
Medical costs
 
26,026

 
23,523

 
51,715

 
46,731

Operating costs
 
5,852

 
5,206

 
11,801

 
10,400

Cost of products sold
 
1,111

 
929

 
2,211

 
1,821

Depreciation and amortization
 
379

 
364

 
757

 
724

Total operating costs
 
33,368

 
30,022

 
66,484

 
59,676

Earnings from operations
 
2,895

 
2,552

 
5,535

 
4,606

Interest expense
 
(151
)
 
(155
)
 
(301
)
 
(315
)
Earnings before income taxes
 
2,744

 
2,397

 
5,234

 
4,291

Provision for income taxes
 
(1,159
)
 
(989
)
 
(2,236
)
 
(1,784
)
Net earnings
 
$
1,585

 
$
1,408

 
$
2,998

 
$
2,507

Earnings per common share:
 
 
 
 
 
 
 
 
Basic
 
$
1.66

 
$
1.44

 
$
3.15

 
$
2.56

Diluted
 
$
1.64

 
$
1.42

 
$
3.10

 
$
2.52

Basic weighted-average number of common shares outstanding
 
952

 
979

 
953

 
981

Dilutive effect of common share equivalents
 
14

 
12

 
14

 
13

Diluted weighted-average number of common shares outstanding
 
966

 
991

 
967

 
994

Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents
 
8

 
8

 
8

 
9

Cash dividends declared per common share
 
$
0.5000

 
$
0.3750

 
$
0.8750

 
$
0.6550


See Notes to the Condensed Consolidated Financial Statements

2

Table of Contents


UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)

 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
(in millions)
 
2015
 
2014
 
2015
 
2014
Net earnings
 
$
1,585

 
$
1,408

 
$
2,998

 
$
2,507

Other comprehensive (loss) income:
 
 
 
 
 
 
 
 
Gross unrealized (losses) gains on investment securities during the period
 
(222
)
 
314

 
(117
)
 
480

Income tax effect
 
80

 
(114
)
 
43

 
(175
)
Total unrealized (losses) gains, net of tax
 
(142
)
 
200

 
(74
)
 
305

Gross reclassification adjustment for net realized gains included in net earnings
 
(68
)
 
(107
)
 
(71
)
 
(153
)
Income tax effect
 
25

 
39

 
26

 
56

Total reclassification adjustment, net of tax
 
(43
)
 
(68
)
 
(45
)
 
(97
)
Total foreign currency translation gains (losses)
 
163

 
151

 
(796
)
 
410

Other comprehensive (loss) income
 
(22
)
 
283

 
(915
)
 
618

Comprehensive income
 
$
1,563

 
$
1,691

 
$
2,083

 
$
3,125


See Notes to the Condensed Consolidated Financial Statements

3

Table of Contents

UnitedHealth Group
Condensed Consolidated Statements of Changes in Shareholders’ Equity
(Unaudited)
 
 
Common Stock
 
Additional Paid-In Capital
 
Retained Earnings
 
Accumulated Other Comprehensive (Loss) Income
 
Total Shareholders’
Equity
(in millions)
 
Shares
 
Amount
 
 
 
Net Unrealized Gains (Losses) on Investments
 
Foreign Currency Translation (Losses) Gains
 
Balance at January 1, 2015
 
954

 
$
10

 
$

 
$
33,836

 
$
223

 
$
(1,615
)
 
$
32,454

Net earnings
 
 
 
 
 
 
 
2,998

 
 
 
 
 
2,998

Other comprehensive loss
 
 
 
 
 
 
 
 
 
(119
)
 
(796
)
 
(915
)
Issuances of common shares, and related tax effects
 
7

 

 
23

 
 
 
 
 
 
 
23

Share-based compensation, and related tax benefits
 
 
 
 
 
319

 
 
 
 
 
 
 
319

Noncontrolling interests fair value and other adjustments
 
 
 
 
 
(73
)
 
 
 
 
 
 
 
(73
)
Common share repurchases
 
(9
)
 

 
(214
)
 
(739
)
 
 
 
 
 
(953
)
Cash dividends paid on common shares
 
 
 
 
 
 
 
(833
)
 
 
 
 
 
(833
)
Balance at June 30, 2015
 
952

 
$
10

 
$
55

 
$
35,262

 
$
104

 
$
(2,411
)
 
$
33,020

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at January 1, 2014
 
988

 
$
10

 
$

 
$
33,047

 
$
54

 
$
(962
)
 
$
32,149

Net earnings
 
 
 
 
 
 
 
2,507

 
 
 
 
 
2,507

Other comprehensive income
 
 
 
 
 
 
 
 
 
208

 
410

 
618

Issuances of common shares, and related tax effects
 
10

 

 
23

 
 
 
 
 
 
 
23

Share-based compensation, and related tax benefits
 
 
 
 
 
217

 
 
 
 
 
 
 
217

Common share repurchases
 
(25
)
 

 
(240
)
 
(1,697
)
 
 
 
 
 
(1,937
)
Cash dividends paid on common shares
 
 
 
 
 
 
 
(642
)
 
 
 
 
 
(642
)
Balance at June 30, 2014
 
973

 
$
10

 
$

 
$
33,215

 
$
262

 
$
(552
)
 
$
32,935



See Notes to the Condensed Consolidated Financial Statements

4

Table of Contents

UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 
 
Six Months Ended
June 30,
(in millions)
 
2015
 
2014
Operating activities
 
 
 
 
Net earnings
 
$
2,998

 
$
2,507

Noncash items:
 
 
 
 
Depreciation and amortization
 
757

 
724

Deferred income taxes
 
(30
)
 
(16
)
Share-based compensation
 
211

 
188

Other, net
 
(160
)
 
(148
)
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
 
 
 
 
Accounts receivable
 
(1,725
)
 
(2,131
)
Other assets
 
(2,178
)
 
(1,135
)
Medical costs payable
 
1,988

 
560

Accounts payable and other liabilities
 
1,809

 
2,219

Other policy liabilities
 
208

 
(218
)
Unearned revenues
 
(446
)
 
(128
)
Cash flows from operating activities
 
3,432

 
2,422

Investing activities
 
 
 
 
Purchases of investments
 
(4,286
)
 
(5,477
)
Sales of investments
 
2,260

 
4,393

Maturities of investments
 
1,622

 
1,544

Cash paid for acquisitions, net of cash assumed
 
(1,778
)
 
(523
)
Purchases of property, equipment and capitalized software
 
(716
)
 
(716
)
Other, net
 
48

 
(99
)
Cash flows used for investing activities
 
(2,850
)
 
(878
)
Financing activities
 
 
 
 
Common stock repurchases
 
(953
)
 
(1,937
)
Cash dividends paid
 
(833
)
 
(642
)
Proceeds from common stock issuances
 
242

 
267

Repayments of long-term debt
 
(416
)
 
(172
)
Proceeds from (repayments of) commercial paper, net
 
1,086

 
(101
)
Customer funds administered
 
941

 
333

Other, net
 
(188
)
 
(170
)
Cash flows used for financing activities
 
(121
)
 
(2,422
)
Effect of exchange rate changes on cash and cash equivalents
 
(69
)
 
14

Increase (decrease) in cash and cash equivalents
 
392

 
(864
)
Cash and cash equivalents, beginning of period
 
7,495

 
7,276

Cash and cash equivalents, end of period
 
$
7,887

 
$
6,412


See Notes to the Condensed Consolidated Financial Statements

5

Table of Contents

UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and “the Company”) is a diversified health and well-being company dedicated to helping people live healthier lives and making the health system work better for everyone. Through its diversified family of businesses, the Company leverages core competencies in advanced, enabling technology; health care data, information and intelligence; and clinical care management and coordination to help meet the demands of the health system. The Company offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the SEC (2014 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and revenues, valuation and impairment analysis of goodwill and other intangible assets, estimates of other policy liabilities and other current receivables, valuations of certain investments, and estimates and judgments related to income taxes and contingent liabilities. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
The accounting policies disclosed in Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the 2014 10-K remain unchanged.
Subsequent Events
On July 1, 2015, UnitedHealth Group Incorporated changed its state of incorporation from Minnesota to Delaware pursuant to a plan of conversion. The reincorporation was approved by the Company’s shareholders at its 2015 Annual Meeting of Shareholders held on June 1, 2015. Upon reincorporation, the affairs of UnitedHealth Group Incorporated became subject to the Delaware General Corporation Law, a new certificate of incorporation and new bylaws, and each previously outstanding share of UnitedHealth Group Incorporated’s common stock as a Minnesota corporation (UNH Minnesota) converted into an outstanding share of common stock of UnitedHealth Group Incorporated as a Delaware corporation after the reincorporation (UNH Delaware). The reincorporation was a tax-free reorganization under the U.S. Internal Revenue Code and did not affect the Company’s business operations.
On July 23, 2015, the Company acquired all of the outstanding common shares of Catamaran Corporation (Catamaran) for $12.9 billion in cash and funded Catamaran’s payoff of its outstanding debt and credit facility in connection with the closing. The Company drew its $1.5 billion delayed draw term loan and issued commercial paper and senior unsecured notes to fund the Company’s purchase of Catamaran; see Note 7 of Notes to the Condensed Consolidated Financial Statements for detail on the related July 2015 debt issuance. Catamaran offers retail pharmacy network management, mail service pharmacy, pharmacy claims management and patient-centric specialty pharmacy services to a broad client portfolio, including health plans and employers serving 35 million people, and provides health care information technology solutions to the pharmacy benefits management industry. This acquisition diversifies OptumRx’s customer and business mix, while accelerating its technology leadership and flexible service offerings. As the Catamaran acquisition occurred in the third quarter of 2015, it is not yet practicable to provide disclosures related to the purchase price allocation or pro forma information.
Recently Issued Accounting Standards
In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (ASU 2014-09). ASU 2014-09 will supersede existing revenue

6

Table of Contents

recognition standards with a single model unless those contracts are within the scope of other standards (e.g., an insurance entity’s insurance contracts). The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies can adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. In July 2015, the FASB approved the deferral of ASU 2014-09 for one year and it is effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption at the original effective date, interim and annual periods beginning after December 15, 2016, will be permitted. The Company is currently evaluating the effect of the new revenue recognition guidance.
The Company has determined that there have been no other recently adopted or issued accounting standards that had, or will have, a material impact on its Condensed Consolidated Financial Statements.
2.Investments
A summary of short-term and long-term investments by major security type is as follows:
(in millions)
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair
Value
June 30, 2015
 
 
 
 
 
 
 
 
Debt securities - available-for-sale:
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
$
1,859

 
$
6

 
$
(4
)
 
$
1,861

State and municipal obligations
 
6,196

 
127

 
(17
)
 
6,306

Corporate obligations
 
7,654

 
76

 
(31
)
 
7,699

U.S. agency mortgage-backed securities
 
2,091

 
25

 
(14
)
 
2,102

Non-U.S. agency mortgage-backed securities
 
837

 
8

 
(5
)
 
840

Total debt securities - available-for-sale
 
18,637

 
242

 
(71
)
 
18,808

Equity securities - available-for-sale
 
1,559

 
36

 
(38
)
 
1,557

Debt securities - held-to-maturity:
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
182

 
3

 

 
185

State and municipal obligations
 
15

 

 

 
15

Corporate obligations
 
349

 

 

 
349

Total debt securities - held-to-maturity
 
546

 
3

 

 
549

Total investments
 
$
20,742

 
$
281

 
$
(109
)
 
$
20,914

December 31, 2014
 
 
 
 
 
 
 
 
Debt securities - available-for-sale:
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
$
1,614

 
$
7

 
$
(1
)
 
$
1,620

State and municipal obligations
 
6,456

 
217

 
(5
)
 
6,668

Corporate obligations
 
7,241

 
112

 
(26
)
 
7,327

U.S. agency mortgage-backed securities
 
2,022

 
39

 
(5
)
 
2,056

Non-U.S. agency mortgage-backed securities
 
872

 
12

 
(4
)
 
880

Total debt securities - available-for-sale
 
18,205

 
387

 
(41
)
 
18,551

Equity securities - available-for-sale
 
1,511

 
36

 
(25
)
 
1,522

Debt securities - held-to-maturity:
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
178

 
2

 

 
180

State and municipal obligations
 
19

 

 

 
19

Corporate obligations
 
298

 

 

 
298

Total debt securities - held-to-maturity
 
495

 
2

 

 
497

Total investments
 
$
20,211

 
$
425

 
$
(66
)
 
$
20,570


7

Table of Contents

The amortized cost and fair value of available-for-sale debt securities as of June 30, 2015, by contractual maturity, were as follows:
(in millions)
 
Amortized
Cost
 
Fair
Value
Due in one year or less
 
$
2,010

 
$
2,014

Due after one year through five years
 
6,943

 
7,009

Due after five years through ten years
 
5,016

 
5,067

Due after ten years
 
1,740

 
1,776

U.S. agency mortgage-backed securities
 
2,091

 
2,102

Non-U.S. agency mortgage-backed securities
 
837

 
840

Total debt securities - available-for-sale
 
$
18,637

 
$
18,808

The amortized cost and fair value of held-to-maturity debt securities as of June 30, 2015, by contractual maturity, were as follows:
(in millions)
 
Amortized
Cost
 
Fair
Value
Due in one year or less
 
$
126

 
$
126

Due after one year through five years
 
204

 
205

Due after five years through ten years
 
106

 
107

Due after ten years
 
110

 
111

Total debt securities - held-to-maturity
 
$
546

 
$
549

The fair value of available-for-sale investments with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
 
 
Less Than 12 Months
 
12 Months or Greater
 
 Total
(in millions)
 
Fair
Value
 
Gross
Unrealized
Losses
 
Fair
Value
 
Gross
Unrealized
Losses
 
Fair
Value
 
Gross
Unrealized
Losses
June 30, 2015
 
 
 
 
 
 
 
 
 
 
 
 
Debt securities - available-for-sale:
 
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
$
529

 
$
(4
)
 
$

 
$

 
$
529

 
$
(4
)
State and municipal obligations
 
1,561

 
(16
)
 
22

 
(1
)
 
1,583

 
(17
)
Corporate obligations
 
3,126

 
(27
)
 
229

 
(4
)
 
3,355

 
(31
)
U.S. agency mortgage-backed securities
 
752

 
(10
)
 
126

 
(4
)
 
878

 
(14
)
Non-U.S. agency mortgage-backed securities
 
364

 
(4
)
 
77

 
(1
)
 
441

 
(5
)
Total debt securities - available-for-sale
 
$
6,332

 
$
(61
)
 
$
454

 
$
(10
)
 
$
6,786

 
$
(71
)
Equity securities - available-for-sale
 
$
148

 
$
(9
)
 
$
82

 
$
(29
)
 
$
230

 
$
(38
)
December 31, 2014
 
 
 
 
 
 
 
 
 
 
 
 
Debt securities - available-for-sale:
 
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
$
420

 
$
(1
)
 
$

 
$

 
$
420

 
$
(1
)
State and municipal obligations
 
711

 
(4
)
 
99

 
(1
)
 
810

 
(5
)
Corporate obligations
 
2,595

 
(17
)
 
464

 
(9
)
 
3,059

 
(26
)
U.S. agency mortgage-backed securities
 

 

 
272

 
(5
)
 
272

 
(5
)
Non-U.S. agency mortgage-backed securities
 
254

 
(2
)
 
114

 
(2
)
 
368

 
(4
)
Total debt securities - available-for-sale
 
$
3,980

 
$
(24
)
 
$
949

 
$
(17
)
 
$
4,929

 
$
(41
)
Equity securities - available-for-sale
 
$
107

 
$
(6
)
 
$
88

 
$
(19
)
 
$
195

 
$
(25
)
The Company’s unrealized losses from all securities as of June 30, 2015 were generated from approximately 7,100 positions out of a total of 23,000 positions. The Company believes that it will collect the principal and interest due on its debt securities

8

Table of Contents

that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, noting neither a significant deterioration since purchase nor other factors leading to an other-than-temporary impairment (OTTI). As of June 30, 2015, the Company did not have the intent to sell any of the securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary.
The Company’s investments in equity securities consist of investments in Brazilian real denominated fixed-income funds, employee savings plan related investments, venture capital funds, and dividend paying stocks. The Company evaluated its investments in equity securities for severity and duration of unrealized loss, overall market volatility and other market factors.
Net realized gains reclassified out of accumulated other comprehensive income were from the following sources:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
(in millions)
 
2015
 
2014
 
2015
 
2014
Total OTTI
 
$
(3
)
 
$
(4
)
 
$
(4
)
 
$
(7
)
Portion of loss recognized in other comprehensive income
 

 

 

 

Net OTTI recognized in earnings
 
(3
)
 
(4
)
 
(4
)

(7
)
Gross realized losses from sales
 
(5
)
 
(29
)
 
(11
)
 
(39
)
Gross realized gains from sales
 
76

 
140

 
86

 
199

Net realized gains (included in investment and other income on the Condensed Consolidated Statements of Operations)
 
68

 
107

 
71

 
153

Income tax effect (included in provision for income taxes on the Condensed Consolidated Statements of Operations)
 
(25
)
 
(39
)
 
(26
)
 
(56
)
Realized gains, net of taxes
 
$
43

 
$
68

 
$
45

 
$
97

3.
Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the 2014 10-K.


9

Table of Contents

The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets excluding assets and liabilities, related to a Supplemental Health Insurance Program (AARP Program), which are presented in a separate table below:
(in millions)
 
Quoted Prices
in Active
Markets
(Level 1)
 
Other
Observable
Inputs
(Level 2)
 
Unobservable
Inputs
(Level 3)
 
Total
Fair and Carrying
Value
June 30, 2015
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
7,754

 
$
133

 
$

 
$
7,887

Debt securities - available-for-sale:
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
1,650

 
211

 

 
1,861

State and municipal obligations
 

 
6,306

 

 
6,306

Corporate obligations
 
12

 
7,609

 
78

 
7,699

U.S. agency mortgage-backed securities
 

 
2,102

 

 
2,102

Non-U.S. agency mortgage-backed securities
 

 
834

 
6

 
840

Total debt securities - available-for-sale
 
1,662

 
17,062

 
84

 
18,808

Equity securities - available-for-sale
 
1,226

 
12

 
319

 
1,557

Interest rate swap assets
 

 
54

 

 
54

Total assets at fair value

$
10,642

 
$
17,261

 
$
403

 
$
28,306

Percentage of total assets at fair value
 
38
%
 
61
%
 
1
%
 
100
%
Interest rate swap liabilities
 
$

 
$
33

 
$

 
$
33

December 31, 2014
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
7,472

 
$
23

 
$

 
$
7,495

Debt securities - available-for-sale:
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
1,427

 
193

 

 
1,620

State and municipal obligations
 

 
6,668

 

 
6,668

Corporate obligations
 
2

 
7,257

 
68

 
7,327

U.S. agency mortgage-backed securities
 

 
2,056

 

 
2,056

Non-U.S. agency mortgage-backed securities
 

 
874

 
6

 
880

Total debt securities - available-for-sale
 
1,429

 
17,048

 
74

 
18,551

Equity securities - available-for-sale
 
1,200

 
12

 
310

 
1,522

Interest rate swap assets
 

 
62

 

 
62

Total assets at fair value
 
$
10,101

 
$
17,145

 
$
384

 
$
27,630

Percentage of total assets at fair value
 
37
%
 
62
%
 
1
%
 
100
%
Interest rate swap liabilities
 
$

 
$
55

 
$

 
$
55

Transfers between levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs; there were no transfers between Levels 1, 2 or 3 of any financial assets or liabilities during the six months ended June 30, 2015 or 2014.



10

Table of Contents

The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
 
Quoted Prices
in Active
Markets
(Level 1)
 
Other
Observable
Inputs
(Level 2)
 
Unobservable
Inputs
(Level 3)
 
Total
Fair
Value
 
Total Carrying Value
June 30, 2015
 
 
 
 
 
 
 
 
 
 
Debt securities - held-to-maturity:
 
 
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
$
185

 
$

 
$

 
$
185

 
$
182

State and municipal obligations
 

 

 
15

 
15

 
15

Corporate obligations
 
92

 
10

 
247

 
349

 
349

Total debt securities - held-to-maturity
 
$
277

 
$
10

 
$
262

 
$
549

 
$
546

Other assets
 
$

 
$
473

 
$

 
$
473

 
$
472

Long-term debt and other financing obligations
 
$

 
$
17,755

 
$

 
$
17,755

 
$
16,664

December 31, 2014
 
 
 
 
 
 
 
 
 
 
Debt securities - held-to-maturity:
 
 
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
$
180

 
$

 
$

 
$
180

 
$
178

State and municipal obligations
 

 

 
19

 
19

 
19

Corporate obligations
 
46

 
10

 
242

 
298

 
298

Total debt securities - held-to-maturity
 
$
226

 
$
10

 
$
261

 
$
497

 
$
495

Other assets
 
$

 
$
478

 
$

 
$
478

 
$
484

Long-term debt and other financing obligations
 
$

 
$
18,863

 
$

 
$
18,863

 
$
17,085

Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during the six months ended June 30, 2015 or 2014.
The carrying amounts reported on the Condensed Consolidated Balance Sheets for other current financial assets and liabilities approximate fair value because of their short-term nature. These assets and liabilities are not listed in the table above.
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level 3 inputs is as follows:
 
 
Three Months Ended
 
Six Months Ended
(in millions)
 
Debt
Securities
 
Equity
Securities
 
Total
 
Debt
Securities
 
Equity
Securities
 
Total
June 30, 2015
 
 
 
 
 
 
 
 
 
 
 
 
Balance at beginning of period
 
$
79

 
$
309

 
$
388

 
$
74

 
$
310

 
$
384

Purchases
 
6

 
10

 
16

 
10

 
14

 
24

Sales
 
(2
)
 
(13
)
 
(15
)
 
(2
)
 
(14
)
 
(16
)
Net unrealized gains (losses) in accumulated other comprehensive income
 
1

 

 
1

 
2

 
(5
)
 
(3
)
Net realized gains in investment and other income
 

 
13

 
13

 

 
14

 
14

Balance at end of period
 
$
84

 
$
319

 
$
403

 
$
84

 
$
319

 
$
403

 
 
 
 
 
 
 
 
 
 
 
 
 
June 30, 2014
 
 
 
 
 
 
 
 
 
 
 
 
Balance at beginning of period
 
$
46

 
$
313

 
$
359

 
$
42

 
$
269

 
$
311

Purchases
 
10

 
6

 
16

 
13

 
50

 
63

Sales
 

 
(147
)
 
(147
)
 

 
(151
)
 
(151
)
Net unrealized gains in accumulated other comprehensive income
 
1

 
6

 
7

 
2

 
10

 
12

Net realized gains in investment and other income
 

 
124

 
124

 

 
124

 
124

Balance at end of period
 
$
57

 
$
302

 
$
359

 
$
57

 
$
302

 
$
359


11

Table of Contents

The following table presents quantitative information regarding unobservable inputs that were significant to the valuation of assets measured at fair value on a recurring basis using Level 3 inputs:
 
 
 
 
 
 
 
 
Range
(in millions)
 
Fair Value
 
Valuation Technique
 
Unobservable Input
 
Low
 
High
June 30, 2015
 
 
 
 
 
 
 
 
 
 
Equity securities - available-for-sale
 
 
 
 
 
 
 
 
 
 
Venture capital portfolios
 
$
268

 
Market approach - comparable companies
 
Revenue multiple
 
1.0
 
5.0
 
 
 
 
 
 
EBITDA multiple
 
8.0
 
10.0
 
 
51

 
Market approach - recent transactions
 
Inactive market transactions
 
N/A
 
N/A
Total equity securities
     available-for-sale
 
$
319

 
 
 
 
 
 
 
 
Also included in the Company’s assets measured at fair value on a recurring basis using Level 3 inputs were $84 million of available-for-sale debt securities as of June 30, 2015, which were not significant.
The Company elected to measure the entirety of the AARP Program assets under management at fair value pursuant to the fair value option. See Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the Company’s 2014 10-K for further detail on the AARP Program. The following table presents fair value information about the AARP Program-related financial assets and liabilities:
(in millions)
 
Quoted Prices
in Active
Markets
(Level 1)
 
Other
Observable
Inputs
(Level 2)
 
Total
Fair and Carrying
Value
June 30, 2015
 
 
 
 
 
 
Cash and cash equivalents
 
$
205

 
$

 
$
205

Debt securities:
 
 
 
 
 
 
U.S. government and agency obligations
 
431

 
164

 
595

State and municipal obligations
 

 
96

 
96

Corporate obligations
 

 
1,287

 
1,287

U.S. agency mortgage-backed securities
 

 
400

 
400

Non-U.S. agency mortgage-backed securities
 

 
195

 
195

Total debt securities
 
431

 
2,142

 
2,573

Other investments
 

 
85

 
85

Total assets at fair value
 
$
636

 
$
2,227

 
$
2,863

Other liabilities
 
$
4

 
$
6

 
$
10

December 31, 2014
 
 
 
 
 
 
Cash and cash equivalents
 
$
415

 
$

 
$
415

Debt securities:
 
 
 
 
 
 
U.S. government and agency obligations
 
409

 
245

 
654

State and municipal obligations
 

 
95

 
95

Corporate obligations
 

 
1,200

 
1,200

U.S. agency mortgage-backed securities
 

 
340

 
340

Non-U.S. agency mortgage-backed securities
 

 
177

 
177

Total debt securities
 
409

 
2,057

 
2,466

Other investments
 

 
81

 
81

Total assets at fair value
 
$
824

 
$
2,138

 
$
2,962

Other liabilities
 
$
5

 
$
13

 
$
18


12

Table of Contents

4.
Medicare Part D Pharmacy Benefits
The Condensed Consolidated Balance Sheets include the following amounts associated with the Medicare Part D program:
 
 
June 30, 2015
 
December 31, 2014
(in millions)
 
Subsidies
 
Drug Discount
 
Risk-Share
 
Subsidies
 
Drug Discount
 
Risk-Share
Other current receivables
 
$
1,776

 
$
266

 
$
20

 
$
1,801

 
$
719

 
$
20

Other policy liabilities
 

 
164

 

 

 
302

 

See Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the Company’s 2014 10-K for further detail on Medicare Part D.
5.
Medical Costs Reserve Development
The following table provides details of the Company's medical cost reserve development:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
(in millions)
 
2015
 
2014
 
2015
 
2014
Related to Prior Years
 
$
(10
)
 
$
40

 
$
130

 
$
260

Related to Current Year
 
100

 
90

 
N/A

 
N/A

In the three and six months ended June 30, 2015 and 2014, the medical cost reserve development was driven by a number of individual factors that were not material.
6.
Health Insurance Industry Tax
The Patient Protection and Affordable Care Act and a reconciliation measure, the Health Care and Education Reconciliation Act of 2010 (together, Health Reform Legislation) includes an annual, nondeductible insurance industry tax (Health Insurance Industry Tax). As of June 30, 2015, the liability recorded in accounts payable and accrued liabilities related to the Health Insurance Industry Tax was $1.8 billion. The corresponding deferred cost recorded in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets was $900 million. There was no liability or asset related to the Health Insurance Industry Tax recorded as of December 31, 2014 as the Health Insurance Industry Tax was paid in September 2014 and the asset was fully expensed by year end. See Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the Company’s 2014 10-K for further detail on the Health Insurance Industry Tax.

13

Table of Contents

7.     Commercial Paper and Long-Term Debt
Commercial paper and senior unsecured long-term debt consisted of the following:
 
 
June 30, 2015
 
December 31, 2014
(in millions, except percentages)
 
Par
Value
 
Carrying
Value
 
Fair
Value
 
Par
Value
 
Carrying
Value
 
Fair
Value
Commercial paper
 
$
1,407

 
$
1,407

 
$
1,407

 
$
321

 
$
321

 
$
321

4.875% notes due March 2015 (a)
 

 

 

 
416

 
419

 
419

0.850% notes due October 2015 (a)
 
625

 
625

 
625

 
625

 
625

 
627

5.375% notes due March 2016 (a)
 
601

 
614

 
620

 
601

 
623

 
634

1.875% notes due November 2016 (a)
 
400

 
399

 
405

 
400

 
397

 
406

5.360% notes due November 2016
 
95

 
95

 
101

 
95

 
95

 
103

6.000% notes due June 2017 (a)
 
441

 
463

 
480

 
441

 
466

 
489

1.400% notes due October 2017 (a)
 
625

 
621

 
626

 
625

 
616

 
624

6.000% notes due November 2017 (a)
 
156

 
163

 
174

 
156

 
164

 
175

1.400% notes due December 2017 (a)
 
750

 
750

 
749

 
750

 
745

 
749

6.000% notes due February 2018 (a)
 
1,100

 
1,111

 
1,223

 
1,100

 
1,106

 
1,238

1.625% notes due March 2019 (a)
 
500

 
499

 
494

 
500

 
496

 
493

2.300% notes due December 2019 (a)
 
500

 
499

 
501

 
500

 
496

 
502

3.875% notes due October 2020 (a)
 
450

 
451

 
481

 
450

 
450

 
477

4.700% notes due February 2021 (a)
 
400

 
413

 
441

 
400

 
413

 
450

3.375% notes due November 2021 (a)
 
500

 
495

 
514

 
500

 
496

 
519

2.875% notes due December 2021 (a)
 
750

 
747

 
750

 
750

 
748

 
759

2.875% notes due March 2022 (a)
 
1,100

 
1,043

 
1,068

 
1,100

 
1,042

 
1,104

0.000% notes due November 2022
 
15

 
10

 
11

 
15

 
10

 
11

2.750% notes due February 2023 (a)
 
625

 
602

 
598

 
625

 
604

 
613

2.875% notes due March 2023 (a)
 
750

 
771

 
722

 
750

 
777

 
745

5.800% notes due March 2036
 
850

 
845

 
988

 
850

 
845

 
1,052

6.500% notes due June 2037
 
500

 
495

 
631

 
500

 
495

 
670

6.625% notes due November 2037
 
650

 
646

 
833

 
650

 
646

 
888

6.875% notes due February 2038
 
1,100

 
1,085

 
1,447

 
1,100

 
1,085

 
1,544

5.700% notes due October 2040
 
300

 
298

 
351

 
300

 
298

 
378

5.950% notes due February 2041
 
350

 
348

 
417

 
350

 
348

 
455

4.625% notes due November 2041
 
600

 
593

 
599

 
600

 
593

 
646

4.375% notes due March 2042
 
502

 
486

 
487

 
502

 
486

 
536

3.950% notes due October 2042
 
625

 
612

 
565

 
625

 
611

 
621

4.250% notes due March 2043
 
750

 
740

 
709

 
750

 
740

 
786

Total commercial paper and long-term debt
 
$
18,017

 
$
17,926

 
$
19,017

 
$
17,347

 
$
17,256

 
$
19,034

(a)
Fixed-rate debt instruments hedged with interest rate swap contracts. See below for more information on the Company’s interest rate swaps.
The Company’s long-term debt obligations also included $145 million and $150 million of other financing obligations, of which $47 million and $34 million were current as of June 30, 2015 and December 31, 2014, respectively.
Commercial Paper and Bank Credit Facilities
Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through broker-dealers. As of June 30, 2015, the Company’s outstanding commercial paper had a weighted-average annual interest rate of 0.3%.
The Company has $3.0 billion five-year and $1.0 billion 364-day revolving bank credit facilities with 23 banks, which mature in November 2019 and November 2015, respectively. The Company also has a $2.0 billion 364-day revolving bank credit facility with 22 banks maturing in April 2016. These facilities provide liquidity support for the Company’s commercial paper program and are available for general corporate purposes. In addition, the Company has a $1.5 billion delayed draw term loan to fund the Catamaran acquisition. As of June 30, 2015, no amounts had been drawn on any of the bank credit facilities or the term loan. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company’s senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities and the term loan as of June 30, 2015, annual interest rates would have ranged from 1.0% to 1.3%.

14

Table of Contents

July 2015 Debt Issuance
In July 2015, the Company issued commercial paper and senior unsecured notes and drew on its delayed draw term loan. The proceeds of these debt issuances were used to fund the Catamaran acquisition. For more detail on the Catamaran acquisition see Note 1 of the Notes to the Condensed Consolidated Financial Statements.
(in millions, except percentages)
 
Par
Value
Floating rate notes due January 2017
 
$
750

1.450% notes due July 2017
 
750

1.900% notes due July 2018
 
1,500

2.700% notes due July 2020
 
1,500

3.350% notes due July 2022
 
1,000

3.750% notes due July 2025
 
2,000

4.625% notes due July 2035
 
1,000

4.750% notes due July 2045
 
2,000

Total July 2015 Issuance
 
$
10,500

Delayed draw term loan
 
$
1,500

Commercial paper
 
$
2,400

Debt Covenants
The Company’s bank credit facilities contain various covenants including requiring the Company to maintain a debt to debt-plus-equity ratio of not more than 50%. The Company was in compliance with its debt covenants as of June 30, 2015.
Interest Rate Swap Contracts
The Company uses interest rate swap contracts to convert a portion of its interest rate exposure from fixed rates to floating rates to more closely align interest expense with interest income received on its variable rate financial assets. The floating rates are benchmarked to LIBOR. The swaps are designated as fair value hedges on the Company’s fixed-rate debt. Since the critical terms of the swaps match those of the debt being hedged, they are considered to be highly effective hedges and all changes in the fair values of the swaps are recorded as adjustments to the carrying value of the related debt with no net impact recorded on the Condensed Consolidated Statements of Operations. Both the hedge fair value changes and the offsetting debt adjustments are recorded in interest expense on the Condensed Consolidated Statements of Operations. The following table summarizes the location and fair value of the interest rate swap fair value hedges on the Company’s Condensed Consolidated Balance Sheet:
Type of Fair Value Hedge
 
Notional Amount
 
Fair Value
 
Balance Sheet Location
 
 
(in billions)
 
(in millions)
 
 
June 30, 2015
 
 
 
 
 
 
Interest rate swap contracts
 
$
10.3

 
54

 
Other assets
 
 
 
 
33

 
Other liabilities
 
 
 
 
 
 
 
December 31, 2014
 
 
 
 
 
 
Interest rate swap contracts
 
$
10.7

 
$
62

 
Other assets

 
 
 
55

 
Other liabilities
The following table provides a summary of the effect of changes in fair value of fair value hedges on the Company’s Condensed Consolidated Statements of Operations:
 
 
Three Months Ended June 30,
 
Six Months Ended
 June 30,
(in millions)
 
2015
 
2014
 
2015
 
2014
Hedge - interest rate swap (loss) gain recognized in interest expense
 
$
(208
)
 
$
67

 
$
14

 
$
133

Hedged item - long-term debt gain (loss) recognized in interest expense
 
208

 
(67
)
 
(14
)
 
(133
)
Net impact on the Company’s Condensed Consolidated Statements of Operations
 
$

 
$

 
$

 
$


15

Table of Contents

8.
Shareholders' Equity
Share Repurchase Program
Under its Board of Directors’ authorization, the Company maintains a share repurchase program. The objectives of the share repurchase program are to optimize the Company’s capital structure and cost of capital, thereby improving returns to shareholders, as well as to offset the dilutive impact of share-based awards. Repurchases may be made from time to time in open market purchases or other types of transactions (including prepaid or structured repurchase programs), subject to certain Board restrictions. During the six months ended June 30, 2015, the Company repurchased 9 million shares at an average price of $111.56 per share and an aggregate cost of $953 million. As of June 30, 2015, the Company had Board authorization to purchase up to 63 million shares of its common stock.
Dividends
In June 2015, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to equal an annual dividend rate of $2.00 per share compared to the annual dividend rate of $1.50 per share, which the Company had paid since June 2014. Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.
The following table provides details of the Company’s 2015 dividend payments:
Payment Date
 
Amount per Share
 
Total Amount Paid
 
 
 
 
(in millions)
March 24, 2015
 
$
0.3750

 
$
357

June 24, 2015
 
0.5000

 
476

9.
Share-Based Compensation
In June 2015, the Company’s shareholders approved an amendment to the 2011 Stock Incentive Plan (Plan). The approved amendment increased the number of shares authorized for issuance under the Plan by 70 million and removed the limit in the Plan for shares other than options and stock-settled stock appreciation rights (SARs) that can be awarded. The Company’s outstanding share-based awards consist mainly of nonqualified stock options, SARs and restricted stock and restricted stock units (collectively, restricted shares). As of June 30, 2015, the Company had 85 million shares available for future grants of share-based awards under its share-based compensation plan.
Stock Options and SARs
Stock option and SAR activity for the six months ended June 30, 2015 is summarized in the table below:
 
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-
Average
Remaining
Contractual Life
 
Aggregate
Intrinsic Value
 
(in millions)
 
 
 
(in years)
 
(in millions)
Outstanding at beginning of period
33

 
$
53

 
 
 
 
Granted
8

 
109

 
 
 
 
Exercised
(6
)
 
52

 
 
 
 
Outstanding at end of period
35

 
66

 
6.2

 
$
1,971

Exercisable at end of period
18

 
47

 
3.7

 
1,335

Vested and expected to vest, end of period
34

 
66

 
6.1

 
1,933

Restricted Shares
Restricted share activity for the six months ended June 30, 2015 is summarized in the table below:
(shares in millions)
 
Shares
 
Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period
 
9

 
$
61

Granted
 
2

 
109

Vested
 
(4
)
 
57

Nonvested at end of period
 
7

 
79


16

Table of Contents

Other Share-Based Compensation Data
(in millions, except per share amounts)
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2015
 
2014
 
2015
 
2014
Stock Options and SARs
 
 
 
 
 
 
 
 
Weighted-average grant date fair value of shares granted, per share
 
$
21

 
$
19

 
$
23

 
$
22

Total intrinsic value of stock options and SARs exercised
 
107

 
74

 
328

 
286

Restricted Shares
 
 
 
 
 
 
 
 
Weighted-average grant date fair value of shares granted, per share
 
118

 
80

 
109

 
70

Total fair value of restricted shares vested
 
12

 
9

 
407

 
423

Share-Based Compensation Items
 
 
 
 
 
 
 
 
Share-based compensation expense, before tax
 
86

 
83

 
211

 
188

Share-based compensation expense, net of tax effects
 
76

 
71

 
177

 
157

Income tax benefit realized from share-based award exercises
 
36

 
24

 
174

 
143

(in millions, except years)
 
June 30, 2015
Unrecognized compensation expense related to share awards
 
$
551

Weighted-average years to recognize compensation expense
 
1.4

Share-Based Compensation Recognition and Estimates
The principal assumptions the Company used in calculating grant-date fair value for stock options and SARs were as follows:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2015
 
2014
 
2015
 
2014
Risk-free interest rate
 
1.7%
 
1.8%
 
1.6% - 1.7%
 
1.7% - 1.8%
Expected volatility
 
22.5%
 
31.7%
 
22.5% - 24.1%
 
31.7% - 39.6%
Expected dividend yield
 
1.7%
 
1.9%
 
1.4% - 1.7%
 
1.6% - 1.9%
Forfeiture rate
 
5.0%
 
5.0%
 
5.0%
 
5.0%
Expected life in years
 
5.6
 
5.4
 
5.6 - 6.1
 
5.4
10.
Commitments and Contingencies
Legal Matters
Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims, and claims related to health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred.
Litigation Matters
California Claims Processing Matter. On January 25, 2008, the California Department of Insurance (CDI) issued an Order to Show Cause to PacifiCare Life and Health Insurance Company, a subsidiary of the Company, alleging violations of certain insurance statutes and regulations related to an alleged failure to include certain language in standard claims correspondence, timeliness and accuracy of claims processing, interest payments, care provider contract implementation, care provider dispute resolution and other related matters. Although the Company believes that CDI had never before issued a fine in excess of $8

17

Table of Contents

million, CDI advocated a fine of approximately $325 million in this matter. The matter was the subject of an administrative hearing before a California administrative law judge beginning in December 2009, and in August 2013, the administrative law judge issued a nonbinding proposed decision recommending a fine of $11.5 million. The California Insurance Commissioner rejected the administrative law judge’s recommendation and on June 9, 2014, issued his own decision imposing a fine of approximately $174 million. On July 10, 2014, the Company filed a lawsuit in California state court challenging the Commissioner’s decision. The Company cannot reasonably estimate the range of loss, if any, that may result from this matter given the procedural status of the dispute, the wide range of possible outcomes, the legal issues presented (including the legal basis for the majority of the alleged violations), the inherent difficulty in predicting a regulatory fine in the event of a remand, and the various remedies and levels of judicial review that remain available to the Company.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments, the Brazilian national regulatory agency for private health insurance and plans (the Agência Nacional de Saúde Suplementar), state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the Brazilian federal revenue service (the Secretaria da Receita Federal), the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Defense Contract Audit Agency and other governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other things, compliance with coding and other requirements under the Medicare risk-adjustment model.
In February 2012, CMS announced a final Risk Adjustment Data Validation (RADV) audit and payment adjustment methodology and that it will conduct RADV audits beginning with the 2011 payment year. These audits involve a review of medical records maintained by care providers and may result in retrospective adjustments to payments made to health plans. CMS has not communicated how the final payment adjustment under its methodology will be implemented.
The Company cannot reasonably estimate the range of loss, if any, that may result from any material government investigations, audits and reviews in which it is currently involved given the inherent difficulty in predicting regulatory action, fines and penalties, if any, and the various remedies and levels of judicial review available to the Company in the event of an adverse finding.
Guaranty Fund Assessments
Under state guaranty fund laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies. In 2009, the Pennsylvania Insurance Commissioner placed long term care insurer Penn Treaty Network America Insurance Company and its subsidiary (Penn Treaty), neither of which is affiliated with the Company, in rehabilitation and petitioned a state court for approval to liquidate Penn Treaty. In 2012, the court denied the liquidation petition and ordered the Insurance Commissioner to submit a rehabilitation plan. The court held a hearing on July 13, 2015 to begin its consideration of the latest proposed rehabilitation plan.
If the current proposed rehabilitation plan, which contemplates the partial liquidation of Penn Treaty, is approved by the court, the Company’s insurance entities and other insurers may be required to pay a portion of Penn Treaty’s policyholder claims through state guaranty association assessments in future periods. The Company intends to vigorously challenge the proposed rehabilitation plan. The Company is currently unable to estimate losses or ranges of losses because the Company cannot predict whether, when or to what extent Penn Treaty will ultimately be declared insolvent, the amount of the insolvency, if any, the amount and timing of any associated guaranty fund assessments or the availability and amount of any premium tax and other potential offsets.

18

Table of Contents

11.
Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. For more information on the Company’s segments see Part I, Item I, “Business” and Note 13 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in the Company's 2014 10-K.
The following table presents the reportable segment financial information:
 
 
 
 
Optum
 
 
 
 
(in millions)
 
UnitedHealthcare
 
OptumHealth
 
OptumInsight
 
OptumRx
 
Optum Eliminations
 
Optum
 
Corporate and
Eliminations
 
Consolidated
Three Months Ended June 30, 2015
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Premiums
 
$
31,186

 
$
775

 
$

 
$

 
$

 
$
775

 
$

 
$
31,961

Services
 
1,715

 
579

 
542

 
29

 

 
1,150

 

 
2,865

Products
 
1

 
11

 
16

 
1,195

 

 
1,222

 

 
1,223

Total revenues - external customers
 
32,902

 
1,365

 
558

 
1,224

 

 
3,147

 

 
36,049

Total revenues - intersegment
 

 
2,031

 
851

 
7,688

 
(172
)
 
10,398

 
(10,398
)
 

Investment and other income
 
171

 
42

 

 
1

 

 
43

 

 
214

Total revenues
 
$
33,073

 
$
3,438

 
$
1,409

 
$
8,913

 
$
(172
)
 
$
13,588

 
$
(10,398
)
 
$
36,263

Earnings from operations
 
$
2,031

 
$
253

 
$
271

 
$
340

 
$

 
$
864

 
$

 
$
2,895

Interest expense
 

 

 

 

 

 

 
(151
)
 
(151
)
Earnings before income taxes
 
$
2,031

 
$
253

 
$
271

 
$
340

 
$

 
$
864

 
$
(151
)
 
$
2,744

Three Months Ended June 30, 2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Premiums
 
$
28,213

 
$
627

 
$

 
$

 
$

 
$
627

 
$

 
$
28,840

Services
 
1,646

 
242

 
532

 
27

 

 
801

 

 
2,447

Products
 
1

 
4

 
14

 
1,018

 

 
1,036

 

 
1,037

Total revenues - external customers
 
29,860

 
873

 
546

 
1,045

 

 
2,464

 

 
32,324

Total revenues - intersegment
 

 
1,674

 
697

 
6,955

 
(115
)
 
9,211

 
(9,211
)
 

Investment and other income
 
211

 
39

 

 

 

 
39

 

 
250

Total revenues
 
$
30,071

 
$
2,586

 
$
1,243

 
$
8,000

 
$
(115
)
 
$
11,714

 
$
(9,211
)
 
$
32,574

Earnings from operations
 
$
1,824

 
$
224

 
$
213

 
$
291

 
$

 
$
728

 
$

 
$
2,552

Interest expense
 

 

 

 

 

 

 
(155
)
 
(155
)
Earnings before income taxes
 
$
1,824

 
$
224

 
$
213

 
$
291

 
$

 
$
728

 
$
(155
)
 
$
2,397


19

Table of Contents

 
 
 
 
Optum
 
 
 
 
(in millions)
 
UnitedHealthcare
 
OptumHealth
 
OptumInsight
 
OptumRx
 
Optum Eliminations
 
Optum
 
Corporate and
Eliminations
 
Consolidated
Six Months Ended June 30, 2015
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Premiums
 
$
62,091

 
$
1,544

 
$

 
$

 
$

 
$
1,544

 
$

 
$
63,635

Services
 
3,318

 
1,100

 
1,101

 
52

 

 
2,253

 

 
5,571

Products
 
1

 
16

 
36

 
2,400

 

 
2,452

 

 
2,453

Total revenues - external customers
 
65,410

 
2,660

 
1,137

 
2,452

 

 
6,249

 

 
71,659

Total revenues - intersegment
 

 
3,994

 
1,662

 
14,755

 
(331
)
 
20,080

 
(20,080
)
 

Investment and other income
 
286

 
73

 

 
1

 

 
74

 

 
360

Total revenues
 
$
65,696

 
$
6,727

 
$
2,799

 
$
17,208

 
$
(331
)
 
$
26,403

 
$
(20,080
)
 
$
72,019

Earnings from operations
 
$
3,929

 
$
487

 
$
493

 
$
626

 
$

 
$
1,606

 
$

 
$
5,535

Interest expense
 

 

 

 

 

 

 
(301
)
 
(301
)
Earnings before income taxes
 
$
3,929

 
$
487

 
$
493

 
$
626

 
$

 
$
1,606

 
$
(301
)
 
$
5,234

Six Months Ended June 30, 2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Premiums
 
$
55,724

 
$
1,231

 
$

 
$

 
$

 
$
1,231

 
$

 
$
56,955

Services
 
3,232

 
505

 
1,057

 
57

 

 
1,619

 

 
4,851

Products
 
2

 
11

 
40

 
1,982

 

 
2,033

 

 
2,035

Total revenues - external customers
 
58,958

 
1,747

 
1,097

 
2,039

 

 
4,883

 

 
63,841

Total revenues - intersegment
 

 
3,345

 
1,393

 
13,419

 
(230
)
 
17,927

 
(17,927
)
 

Investment and other income
 
367

 
74

 

 

 

 
74

 

 
441

Total revenues
 
$
59,325

 
$
5,166

 
$
2,490

 
$
15,458

 
$
(230
)
 
$
22,884

 
$
(17,927
)
 
$
64,282

Earnings from operations
 
$
3,228

 
$
435

 
$
410

 
$
533

 
$

 
$
1,378

 
$

 
$
4,606

Interest expense
 

 

 

 

 

 

 
(315
)
 
(315
)
Earnings before income taxes
 
$
3,228

 
$
435

 
$
410

 
$
533

 
$

 
$
1,378

 
$
(315
)
 
$
4,291


ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and Notes and with our 2014 10-K, including the Consolidated Financial Statements and Notes in Part II, Item 8, “Financial Statements” in that report. Unless the context indicates otherwise, references to the terms “UnitedHealth Group,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2014 10-K and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a diversified health and well-being company dedicated to helping people live healthier lives and making the health system work better for everyone. Through our diversified family of businesses, we leverage core competencies in advanced, enabling technology; health care data, information and intelligence; and clinical care management and coordination to help meet the demands of the health system. We offer a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services.
Further information on our business is included in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2014 10-K and additional information on our segments can be found in this Item 2 and in Note 11 of Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of this report.
Business Trends
Our businesses participate in the U.S., Brazilian and certain other international health economies. In the United States, health care spending comprises approximately 18% of gross domestic product and has grown consistently for many years. We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macro-economic conditions and regulatory changes, including enacted health reform legislation in the United States, which have impacted and could further impact our results of operations.
Pricing Trends. To price our health care benefit products, we start with our view of expected future costs. We frequently evaluate and adjust our approach in each of the local markets we serve, considering all relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations. Our review of regulatory considerations involves a focus on minimum loss ratio (MLR) thresholds and the risk adjustment, risk corridor and reinsurance provisions that impact the small group and individual markets. We will continue seeking to balance growth and profitability across all of these dimensions.
We continue to be under pressure from ongoing market competition in commercial products and from government payment rates. The intensity of commercial pricing competition depends on local market conditions and competitive dynamics. Annual commercial premium rate increases are subject to federal and state review and approval procedures. The Medicare Advantage rate structure is changing and funding has been cut in recent years, with additional reductions taking effect in 2015, as discussed below in “Regulatory Trends and Uncertainties.” Although we expect continued Medicaid revenue increases due to anticipated growth in the number of people served through our offerings, the reimbursement rate environment creates the risk of downward pressure on Medicaid net margin percentages.
Medical Cost Trends. Our medical cost trends are primarily related to changes in unit costs, health system utilization and prescription drug costs. Although Health Reform Legislation and prescription drug utilization, particularly use of new specialty medications, have exerted upward pressure on medical cost trends, our medical cost management strategies have had a moderating impact on utilization trends in recent years.
Regulatory Trends and Uncertainties
Following is a summary of management’s view of the trends and uncertainties related to some of the key provisions of Health Reform Legislation and other regulatory items. For additional information regarding Health Reform Legislation and regulatory trends and uncertainties, see Part I, Item 1, “Business - Government Regulation”, Item 1A, “Risk Factors”, and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2014 10-K.
Medicare Advantage Rates. Medicare Advantage rates have been cut over the last several years, with additional funding reductions to be phased-in through 2017. The impact of these cuts to our 2015 Medicare Advantage revenues is partially mitigated by reductions in provider reimbursements for those care providers with rates indexed to Medicare Advantage revenues or Medicare fee-for-service reimbursement rates. These factors affected our plan benefit designs, market participation, growth prospects and earnings expectations for our Medicare Advantage plans this year.
The 2016 Final Rate notice released by CMS in April 2015 provided some progress toward more stable program rates, with the industry seeing an average increase in funding of 125 basis points. However, these rates still trail the pace of the rising cost of medical care and create continued pressure on the Medicare Advantage program. 
Our Medicare Advantage rates are currently enhanced by CMS quality bonuses in certain counties based on our local plans’ star ratings. The level of star ratings from CMS, based upon specified clinical and operational performance standards, will impact future quality bonuses. In addition, star ratings affect the amount of savings a plan has to generate to offer supplemental benefits, which ultimately may affect the plan’s membership and revenue. The previous star bonus program, which paid bonuses to qualifying plans rated 3 stars or higher, expired after 2014. In 2015, quality bonus payments will be paid only to plans rated 4 stars and higher. For the 2015 star bonus payment year, 39% of our Medicare Advantage members are enrolled in plans rated 4 stars or higher. We are dedicating substantial resources to advance our quality scores and star ratings to strengthen our local market programs and further improve our performance in future years.

20

Table of Contents

Health Insurance Industry Tax and Premium Stabilization Programs. Health Reform Legislation includes a Health Insurance Industry Tax levied on risk-based products proportionally across the industry. The industry-wide amount of the annual tax is $11.3 billion in 2015 and we expect that our proportionate share will be $1.8 billion. Health Reform Legislation also includes three programs designed to stabilize the health insurance markets. These programs encompass: a temporary reinsurance program; a temporary risk corridors program; and a permanent risk adjustment program. Of the $8 billion allocated for the reinsurance program in 2015, $6 billion will fund the reinsurance pool and $2 billion will fund the U.S. Treasury. While funding for the reinsurance program will come from all commercial lines of business, only market reform compliant individual business will be eligible for reinsurance recoveries.
For further detail on the Health Insurance Industry Tax and Premium Stabilization Programs, see Note 2 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements” in our 2014 10-K.
Exchanges and Coverage Expansion. We and our competitors are adapting product, network and marketing strategies across markets to anticipate new or expanding distribution channels, including public exchanges, private exchanges and off exchange purchasing. In 2015, we are participating in 23 individual public exchanges and in 12 small group public exchanges.
RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share data)
 
Three Months Ended
June 30,
 
Increase/(Decrease)
 
Six Months Ended
June 30,
 
Increase/(Decrease)
 
2015
 
2014
 
2015 vs. 2014
 
2015
 
2014
 
2015 vs. 2014
Revenues:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Premiums
 
$
31,961

 
$
28,840

 
$
3,121

 
11
%
 
$
63,635

 
$
56,955

 
$
6,680

 
12
%
Services
 
2,865

 
2,447

 
418

 
17

 
5,571

 
4,851

 
720

 
15

Products
 
1,223

 
1,037

 
186

 
18

 
2,453

 
2,035

 
418

 
21

Investment and other income
 
214

 
250

 
(36
)
 
(14
)
 
360

 
441

 
(81
)
 
(18
)
Total revenues
 
36,263

 
32,574

 
3,689

 
11

 
72,019

 
64,282

 
7,737

 
12

Operating costs:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical costs
 
26,026

 
23,523

 
2,503

 
11

 
51,715

 
46,731

 
4,984

 
11

Operating costs
 
5,852

 
5,206

 
646

 
12

 
11,801

 
10,400

 
1,401

 
13

Cost of products sold
 
1,111

 
929

 
182

 
20

 
2,211

 
1,821

 
390

 
21

Depreciation and amortization
 
379

 
364

 
15

 
4

 
757

 
724

 
33

 
5

Total operating costs
 
33,368

 
30,022

 
3,346

 
11

 
66,484

 
59,676

 
6,808

 
11

Earnings from operations
 
2,895

 
2,552

 
343

 
13

 
5,535

 
4,606

 
929

 
20

Interest expense
 
(151
)
 
(155
)
 
(4
)
 
(3
)
 
(301
)
 
(315
)
 
(14
)
 
(4
)
Earnings before income taxes
 
2,744

 
2,397

 
347

 
14

 
5,234

 
4,291

 
943

 
22

Provision for income taxes
 
(1,159
)
 
(989
)
 
170

 
17

 
(2,236
)
 
(1,784
)
 
452

 
25

Net earnings
 
$
1,585

 
$
1,408

 
$
177

 
13

 
$
2,998

 
$
2,507

 
$
491

 
20

Diluted earnings per common share
 
$
1.64

 
$
1.42

 
$
0.22

 
15
 %
 
$
3.10

 
$
2.52

 
$
0.58

 
23
 %
Medical care ratio (a)
 
81.4
%
 
81.6
%
 
(0.2
)%
 
 
 
81.3
%
 
82.0
%
 
(0.7
)%
 
 
Operating cost ratio
 
16.1

 
16.0

 
0.1

 
 
 
16.4

 
16.2

 
0.2

 
 
Operating margin
 
8.0

 
7.8

 
0.2

 
 
 
7.7

 
7.2

 
0.5

 
 
Tax rate
 
42.2

 
41.3

 
0.9

 
 
 
42.7

 
41.6

 
1.1

 
 
Net earnings margin
 
4.4

 
4.3

 
0.1

 
 
 
4.2

 
3.9

 
0.3

 
 
Return on equity (b)
 
19.5
%
 
17.2
%
 
2.3
 %
 
 
 
18.5
%
 
15.4
%
 
3.1
 %
 
 

(a)
Medical care ratio is calculated as medical costs divided by premium revenue.
(b)
Return on equity is calculated as annualized net earnings divided by average equity. Average equity is calculated using the equity balance at the end of the preceding year and the equity balances at the end of each of the quarters in the periods presented.

21

Table of Contents

SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select second quarter 2015 year-over-year operating comparisons to second quarter 2014 and other 2015 significant items.
Consolidated revenues grew 11%, UnitedHealthcare revenues grew 10% and Optum revenues grew 16%.
UnitedHealthcare grew to serve an additional 1.6 million people domestically.
Earnings from operations increased 13%, including an increase of 11% at UnitedHealthcare and 19% at Optum.
Diluted earnings per common share increased 15% to $1.64.
Year-to-date 2015 cash flows from operations were $3.4 billion an increase of 42%.
On July 23, 2015, we acquired Catamaran through the purchase of all of its outstanding common stock for cash. See Note 1 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more information about this transaction.
2015 RESULTS OF OPERATIONS COMPARED TO 2014 RESULTS
Consolidated Financial Results
Revenues
The increase in revenues during the three and six months ended June 30, 2015 was primarily driven by growth in the number of individuals served across our benefits businesses and growth across all of Optum’s businesses.
Medical Costs and Medical Care Ratio
Medical costs during the three and six months ended June 30, 2015 increased due to risk-based membership growth in our benefits businesses. The medical care ratio for the three and six months ended June 30, 2015 decreased 20 and 70 basis points, respectively, primarily due to premium increases to cover the 2015 step up in the Health Insurance Industry Tax and our performance in managing health care costs across our benefits businesses.
Operating Cost Ratio
The increase in our operating cost ratio during the three and six months ended June 30, 2015 was due to services business acquisitions, which carry proportionately higher operating costs than premium-based business, largely offset by growth in government benefits programs and productivity gains.

22

Table of Contents

Reportable Segments
See Note 11 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1, “Financial Statements” for more information on our segments. The following table presents a summary of the reportable segment financial information:
 
 
Three Months Ended June 30,
 
Increase/(Decrease)
 
Six Months Ended
June 30,
 
Increase/(Decrease)
(in millions, except percentages)
 
2015
 
2014
 
2015 vs. 2014
 
2015
 
2014
 
2015 vs. 2014
Revenues
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UnitedHealthcare
 
$
33,073

 
$
30,071

 
$
3,002

 
10
%
 
$
65,696

 
$
59,325

 
$
6,371

 
11
%
OptumHealth
 
3,438

 
2,586

 
852

 
33

 
6,727

 
5,166

 
1,561

 
30

OptumInsight
 
1,409

 
1,243

 
166

 
13

 
2,799

 
2,490

 
309

 
12

OptumRx
 
8,913

 
8,000

 
913

 
11

 
17,208

 
15,458

 
1,750

 
11

Optum eliminations
 
(172
)
 
(115
)
 
57

 
50

 
(331
)
 
(230
)
 
101

 
44

Optum
 
13,588

 
11,714

 
1,874

 
16

 
26,403

 
22,884

 
3,519

 
15

Eliminations
 
(10,398
)
 
(9,211
)
 
1,187

 
13

 
(20,080
)
 
(17,927
)
 
2,153

 
12

Consolidated revenues
 
$
36,263

 
$
32,574

 
$
3,689

 
11
%
 
$
72,019

 
$
64,282

 
$
7,737

 
12
%
Earnings from operations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UnitedHealthcare
 
$
2,031

 
$
1,824

 
$
207

 
11
%
 
$
3,929

 
$
3,228

 
$
701

 
22
%
OptumHealth
 
253

 
224

 
29

 
13

 
487

 
435

 
52

 
12

OptumInsight
 
271

 
213

 
58

 
27

 
493

 
410

 
83

 
20

OptumRx
 
340

 
291

 
49

 
17

 
626

 
533

 
93

 
17

Optum
 
864

 
728

 
136

 
19

 
1,606

 
1,378

 
228

 
17

Consolidated earnings from operations
 
$
2,895

 
$
2,552

 
$
343

 
13
%
 
$
5,535

 
$
4,606

 
$
929

 
20
%
Operating margin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UnitedHealthcare
 
6.1
%
 
6.1
%
 
 %
 
 
 
6.0
%
 
5.4
%
 
0.6
 %
 
 
OptumHealth
 
7.4

 
8.7

 
(1.3
)
 
 
 
7.2

 
8.4

 
(1.2
)
 
 
OptumInsight
 
19.2

 
17.1

 
2.1

 
 
 
17.6

 
16.5

 
1.1

 
 
OptumRx
 
3.8

 
3.6

 
0.2

 
 
 
3.6

 
3.4

 
0.2

 
 
Optum
 
6.4

 
6.2

 
0.2

 
 
 
6.1

 
6

 
0.1

 
 
Consolidated operating margin
 
8.0
%
 
7.8
%
 
0.2
 %
 
 
 
7.7
%
 
7.2
%
 
0.5
 %
 
 
UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
 
 
Three Months Ended
June 30,
 
Increase/(Decrease)
 
Six Months Ended
June 30,
 
Increase/(Decrease)
(in millions, except percentages)
 
2015
 
2014
 
2015 vs. 2014
 
2015
 
2014
 
2015 vs. 2014
UnitedHealthcare Employer & Individual
 
$
11,845

 
$
10,729

 
$
1,116

 
10
 %
 
23,268

 
$
21,686

 
$
1,582

 
7
 %
UnitedHealthcare Medicare & Retirement
 
12,559

 
11,785

 
774

 
7

 
25,340

 
23,287

 
2,053

 
9

UnitedHealthcare Community & State
 
7,205

 
5,764

 
1,441

 
25

 
14,110

 
10,938

 
3,172

 
29

UnitedHealthcare Global
 
1,464

 
1,793

 
(329
)
 
(18
)
 
2,978

 
3,414

 
(436
)
 
(13
)
Total UnitedHealthcare revenues
 
$
33,073

 
$
30,071

 
$
3,002

 
10
 %
 
$
65,696

 
$
59,325

 
$
6,371

 
11
 %

23

Table of Contents

The following table summarizes the number of individuals served by our UnitedHealthcare businesses, by major market segment and funding arrangement:
 
 
June 30,
 
Increase/(Decrease)
(in thousands, except percentages)
 
2015
 
2014
 
2015 vs. 2014
Commercial risk-based
 
8,105

 
7,610

 
495

 
7
 %
Commercial fee-based, including TRICARE
 
21,295

 
21,240

 
55

 

Total commercial
 
29,400

 
28,850

 
550

 
2

Medicare Advantage
 
3,205

 
2,985

 
220

 
7

Medicaid
 
5,210

 
4,670

 
540

 
12

Medicare Supplement (Standardized)
 
3,965

 
3,665

 
300

 
8

Total public and senior
 
12,380

 
11,320

 
1,060

 
9

Total UnitedHealthcare - domestic medical
 
41,780

 
40,170

 
1,610

 
4

International
 
4,080

 
4,765

 
(685
)
 
(14
)
Total UnitedHealthcare - medical
 
45,860

 
44,935

 
925

 
2
 %
Supplemental Data:
 
 
 
 
 
 
 
 
Medicare Part D stand-alone
 
5,075

 
5,150

 
(75
)
 
(1
)%
The increase in commercial risk-based enrollment was a result of strong participation in UnitedHealthcare’s individual public exchange products and favorable annual renewal activity and new business wins in the employer group segment. Medicare Advantage participation increased year-over-year primarily due to growth in people served through employer-sponsored group Medicare Advantage plans. Medicaid growth was driven by the combination of ACA Medicaid expansion, states launching new programs to complement established programs and growth in established programs, which was partially offset by a decrease of 175,000 people in one market, where an additional offering was introduced by the state in the first quarter of 2015. Medicare Supplement growth reflected strong customer retention and new sales. The number of people served internationally decreased year-over-year primarily due to pricing and underwriting disciplines in Brazil in response to regulatory actions.
UnitedHealthcare’s revenue growth during the three and six months ended June 30, 2015 was due to growth in the number of individuals served across its businesses and price increases reflecting underlying medical cost trends.
UnitedHealthcare’s operating earnings for the three and six months ended June 30, 2015 increased year-over-year due to a combination of strong growth across the business along with improved medical cost management and increased productivity. 
Optum
Total revenues increased for the three and six months ended June 30, 2015 as each reporting segment advanced revenues by double-digit percentages as a result of the factors discussed below.
The increases in Optum’s earnings from operations for the three and six months ended June 30, 2015 were driven by revenue growth. For the six months ended June 30, 2015, the increase in earnings from operations was partially offset by transaction costs related to the acquisition of Catamaran at OptumRx.
The results by segment were as follows:
OptumHealth
Revenue and earnings from operations increased at OptumHealth during the three and six months ended June 30, 2015 primarily due to growth in the number of patients served across its OptumCare health delivery businesses as well as the impact of acquisitions. The operating margins for the three and six months ended June 30, 2015 decreased from the prior year primarily due to stronger growth in lower margin lines of business and investments made to support future growth.
OptumInsight
Revenue at OptumInsight for the three and six months ended June 30, 2015 increased primarily due to growth in care provider revenue management services. Earnings from operations and operating margins for the three and six months ended June 30, 2015 increased primarily due to increased revenues, growth in technology services and simplification of lines of business.
OptumRx
OptumRx revenue, earnings from operations and operating margin for the three and six months ended June 30, 2015 increased due to an increase in prescription volume driven by serving an increasing number of people, increases in revenue per script and

24

Table of Contents

growth in specialty medications. The increases in earnings from operations and operating margin for the six months ended June 30, 2015 were partially offset by transaction costs related to the acquisition of Catamaran. For more information about the Catamaran transaction, see Note 1 in Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of this report.
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Introduction
We manage our liquidity and financial position in the context of our overall business strategy. We continually forecast and manage our cash, investments, working capital balances and capital structure to meet the short-term and long-term obligations of our businesses while seeking to maintain liquidity and financial flexibility. Cash flows generated from operating activities are principally from earnings before noncash expenses.
Our regulated subsidiaries generate significant cash flows from operations and are subject to financial regulations and standards in their respective jurisdictions. These standards, among other things, require these subsidiaries to maintain specified levels of statutory capital, as defined by each jurisdiction, and restrict the timing and amount of dividends and other distributions that may be paid to their parent companies. In the United States, these regulations and standards are generally consistent with model regulations established by the National Association of Insurance Commissioners. These standards generally permit dividends to be paid from statutory unassigned surplus of the regulated subsidiary and are limited based on the regulated subsidiary’s level of statutory net income and statutory capital and surplus. These dividends are referred to as “ordinary dividends” and generally may be paid without prior regulatory approval. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, the entire dividend is generally considered an “extraordinary dividend” and must receive prior regulatory approval.
For the six months ended June 30, 2015, our U.S. regulated subsidiaries paid their parent companies dividends of $2.4 billion, and we had approximately $1.9 billion in ordinary dividend capacity remaining for the year.
Our nonregulated businesses also generate cash flows from operations that are available for general corporate use. Cash flows generated by these entities, combined with dividends from our regulated entities and financing through the issuance of long-term debt as well as issuance of commercial paper or the ability to draw under our committed credit facilities, further strengthen our operating and financial flexibility. We use these cash flows to expand our businesses through acquisitions, reinvest in our businesses through capital expenditures, repay debt, and return capital to our shareholders through shareholder dividends and/or repurchases of our common stock, depending on market conditions.

25

Table of Contents

Summary of our Major Sources and Uses of Cash and Cash Equivalents
 
 
Six Months Ended June 30,
 
Increase/(Decrease)
(in millions)
 
2015
 
2014
 
2015 vs. 2014
Sources of cash:
 
 
 
 
 
 
Cash provided by operating activities
 
$
3,432

 
$
2,422

 
$
1,010

Customer funds administered
 
941

 
333

 
608

Issuances of commercial paper and long-term debt, net of repayments
 
670

 

 
670

Proceeds from common stock issuances
 
242

 
267

 
(25
)
Sales and maturities of investments, net of purchases
 

 
460

 
(460
)
Other
 
48

 

 
48

Total sources of cash
 
5,333

 
3,482

 
 
Uses of cash:
 
 
 
 
 
 
Common stock repurchases
 
(953
)
 
(1,937
)
 
984

Cash paid for acquisitions, net of cash assumed
 
(1,778
)
 
(523
)
 
(1,255
)
Purchases of investments, net of sales and maturities
 
(404
)
 

 
(404
)
Purchases of property, equipment and capitalized software, net
 
(716
)
 
(716
)
 

Cash dividends paid
 
(833
)
 
(642
)
 
(191
)
Repayments of long-term debt and commercial paper, net of issuances
 

 
(273
)
 
273

Other
 
(188
)
 
(269
)
 
81

Total uses of cash
 
(4,872
)
 
(4,360
)
 
 
Effect of exchange rate changes on cash and cash equivalents
 
(69
)
 
14

 
(83
)
Net increase (decrease) in cash and cash equivalents
 
$
392

 
$
(864
)
 
$
1,256

2015 Cash Flows Compared to 2014 Cash Flows
Cash flows provided by operating activities in 2015 increased primarily due to improvement in net earnings and growth in risk-based products, which increased medical costs payable, partially offset by the first quarter 2015 payment of reinsurance program fees.
Other significant changes in sources or uses of cash year-over-year included decreased share repurchases in 2015 compared to 2014, net debt issuances in 2015 compared to net repayments in 2014, increased cash paid for acquisitions in 2015 compared to 2014, and a change in investment activity to net purchases in 2015 compared to net sales in 2014.
Financial Condition
As of June 30, 2015, our cash, cash equivalent and available-for-sale investment balances of $28.3 billion included $7.9 billion of cash and cash equivalents (of which $654 million was available for general corporate use), $18.8 billion of debt securities and $1.6 billion of investments in equity securities consisting of investments in non-U.S. dollar fixed-income funds; employee savings plan related investments; venture capital funds; and dividend paying stocks. Given the significant portion of our portfolio held in cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. The use of different market assumptions or valuation methodologies, especially those used in valuing our $403 million of available-for-sale Level 3 securities (those securities priced using significant unobservable inputs), may have an effect on the estimated fair values of our investments. Due to the subjective nature of these assumptions, the estimates may not be indicative of the actual exit price if we had sold the investment at the measurement date. Other sources of liquidity, primarily from operating cash flows and our commercial paper program, which is supported by our bank credit facilities, reduce the need to sell investments during adverse market conditions. See Note 3 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for further detail concerning our fair value measurements.
Our available-for-sale debt portfolio had a weighted-average duration of 3.3 years and a weighted-average credit rating of “AA” as of June 30, 2015. When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.

26

Table of Contents

Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows:
Commercial Paper and Bank Credit Facilities. Our bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of unsecured debt through third-party broker-dealers, and are available for general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Our bank credit facilities contain various covenants, including covenants requiring us to maintain a debt to debt-plus-equity ratio of not more than 50%. Our debt to debt-plus-equity ratio, calculated as the sum of debt divided by the sum of debt and shareholders’ equity, which reasonably approximates the actual covenant ratio, was 35.4% as of June 30, 2015.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, for example, to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. In July 2015, we issued debt to fund the acquisition of Catamaran. For more information on this debt issuance, see Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Credit Ratings. Our credit ratings as of June 30, 2015, were as follows:
  
Moody’s
 
Standard & Poor’s
 
Fitch(a)
 
A.M. Best
 
Ratings
 
Outlook
 
Ratings
 
Outlook
 
Ratings
 
Outlook
 
Ratings
 
Outlook
Senior unsecured debt
A3
 
Negative
 
A+
 
Negative
 
A-
 
Negative
Watch
 
bbb+
 
Stable
Commercial paper
P-2
 
n/a
 
A-1
 
n/a
 
F1
 
n/a
 
AMB-2
 
n/a
(a)
In July 2015, Fitch removed us from Negative Watch, affirmed our ratings, and changed our outlook to Negative.
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. For example, a significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. We expect continued moderated share repurchase activity for the remainder of 2015 due to the acquisition of Catamaran. For more information on our share repurchase program, see Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Dividends. In June 2015, our Board increased our quarterly cash dividend to shareholders to an annual dividend rate of $2.00 per share. For more information on our dividend, see Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Catamaran Acquisition. In March 2015, we entered into an agreement to purchase all of Catamaran’s outstanding common shares for cash. The transaction closed on July 23, 2015. We paid for the acquisition primarily with the proceeds of new indebtedness. For more information about the Catamaran transaction and related debt issuances, see Note 1 and Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
A summary of future obligations under our various contractual obligations and commitments as of December 31, 2014 was disclosed in our 2014 10-K. During the six months ended June 30, 2015, other than the Catamaran acquisition, there were no material changes to this previously disclosed information outside the ordinary course of business. However, we continually evaluate opportunities to expand our operations, including through internal development of new products, programs and technology applications and acquisitions.
RECENTLY ISSUED ACCOUNTING STANDARDS
In May 2014, the FASB issued ASU No. 2014-09 “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 will supersede existing revenue recognition standards with a single model unless those contracts are within the scope of other standards (e.g., an insurance entity’s insurance contracts). The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will

27

Table of Contents

be required. Companies can adopt the new standard using either the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. In July 2015, the FASB approved the deferral of ASU 2014-09 for one year and is effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption at the original effective date, interim and annual periods beginning after December 15, 2016, will be permitted. We are currently evaluating the effect of the new revenue recognition guidance.
We have determined that there have been no other recently issued, but not yet adopted, accounting standards that will have a material impact on our Condensed Consolidated Financial Statements.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates, which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from our calculated estimates and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable, revenues, goodwill and intangible assets, investments, income taxes and contingent liabilities. For a detailed description of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our 2014 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8, “Financial Statements” in our 2014 10-K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements within the meaning of the PSLRA. These statements are intended to take advantage of the “safe harbor” provisions of the PSLRA. Generally the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “plan,” “project,” “should” and similar expressions identify forward-looking statements, which generally are not historical in nature. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. We caution that actual results could differ materially from those that management expects, depending on the outcome of certain factors.
Some factors that could cause actual results to differ materially from results discussed or implied in the forward-looking statements include: our ability to effectively estimate, price for and manage our medical costs, including the impact of any new coverage requirements; new laws or regulations, or changes in existing laws or regulations, or their enforcement or application, including increases in medical, administrative, technology or other costs or decreases in enrollment resulting from U.S., Brazilian and other jurisdictions regulations affecting the health care industry; assessments for insolvent payers under state guaranty fund laws; our ability to achieve improvement in CMS star ratings and other quality scores that impact revenue; reductions in revenue or delays to cash flows received under Medicare, Medicaid and TRICARE programs, including sequestration and the effects of a prolonged U.S. government shutdown or debt ceiling constraints; changes in Medicare, including changes in payment methodology, the CMS star ratings program or the application of risk adjustment data validation audits; our participation in federal and state health insurance exchanges which entail uncertainties associated with mix and volume of business; cyber-attacks or other privacy or data security incidents; failure to comply with privacy and data security regulations; regulatory and other risks and uncertainties of the pharmacy benefits management industry; competitive pressures, which could affect our ability to maintain or increase our market share; challenges to our public sector contract awards; our ability to execute contracts on competitive terms with physicians, hospitals and other service providers; failure to achieve targeted operating cost productivity improvements, including savings resulting from technology enhancement and administrative modernization; increases in costs and other liabilities associated with increased litigation, government investigations, audits or reviews; failure to manage successfully our strategic alliances or complete or receive anticipated benefits of acquisitions and other strategic transactions, including our acquisition of Catamaran; fluctuations in foreign currency exchange rates on our reported shareholders equity and results of operations; downgrades in our credit ratings; adverse economic conditions, including decreases in enrollment resulting from increases in the unemployment rate and commercial attrition; the performance of our investment portfolio; impairment of the value of our goodwill and intangible assets in connection with dispositions or if estimated future results do not adequately support goodwill and intangible assets recorded for our existing businesses or the businesses that we acquire; increases in health care costs resulting from large-scale medical emergencies; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; and our ability to obtain sufficient funds from our regulated subsidiaries or the debt or capital markets to

28

Table of Contents

fund our obligations, to maintain our debt to total capital ratio at targeted levels, to maintain our quarterly dividend payment cycle or to continue repurchasing shares of our common stock.
This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain risk factors that may affect our business operations, financial condition and results of operations, in our other periodic and current filings with the SEC, including our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Any or all forward-looking statements we make may turn out to be wrong, and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual future results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by applicable securities laws.
ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our primary market risks are exposures to changes in interest rates that impact our investment income and interest expense and the fair value of certain of our fixed-rate investments and debt, as well as foreign currency exchange rate risk of the U.S. dollar primarily to the Brazilian real.
We manage exposure to market interest rates by diversifying investments across different fixed income market sectors and debt across maturities, as well as by endeavoring to match our floating-rate assets and liabilities over time, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale securities are reported in comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June 30, 2015 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages):
 
 
June 30, 2015
Increase (Decrease) in Market Interest Rate
 
Investment
Income Per
Annum (a)
 
Interest
Expense Per
Annum (a)
 
Fair Value of
Financial Assets (b)
 
Fair Value of
Financial Liabilities
2 %
 
$
197

 
$
263

 
$
(1,374
)
 
$
(1,657
)
1
 
98

 
131

 
(696
)
 
(909
)
(1)
 
(61
)
 
(24
)
 
645

 
1,108

(2)
 
nm

 
nm

 
1,114

 
2,464

nm = not meaningful
(a)
Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of June 30, 2015, the assumed hypothetical change in interest rates does not reflect the full 100 basis point reduction in interest income or interest expense as the rate cannot fall below zero and thus the 200 basis point reduction is not meaningful.
(b)
As of June 30, 2015, some of our investments had interest rates below 2% so the assumed hypothetical change in the fair value of investments does not reflect the full 200 basis point reduction.
We have an exposure to changes in the value of the Brazilian real to the U.S. dollar in translation of Amil’s operating results at the average exchange rate over the accounting period, and Amil’s assets and liabilities at the spot rate at the end of the accounting period. The gains or losses resulting from translating foreign assets and liabilities into U.S. dollars are included in shareholders’ equity and comprehensive income.
An appreciation of the U.S. dollar against the Brazilian real reduces the carrying value of the net assets denominated in Brazilian real. For example, as of June 30, 2015, a hypothetical 10% and 25% increase in the value of the U.S. dollar against the Brazilian real would have caused a reduction in net assets of approximately $370 million and $815 million, respectively. We manage exposure to foreign currency risk by conducting our international business operations primarily in their functional currencies.
ITEM 4.
CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

29

Table of Contents

In connection with the filing of this Form 10-Q, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2015. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2015.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1.
LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 10 of Notes to the Condensed Consolidated Financial Statements contained in Part I, Item 1 of this report.
ITEM 1A.
RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” of our 2014 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2014 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or future results.
There have been no material changes to the risk factors disclosed in our 2014 10-K.
ITEM 2.    UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities (a)
Second Quarter 2015
For the Month Ended
 
Total Number
of Shares
Purchased (b)
 
Average Price
Paid per Share
 
Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs (b)
 
Maximum Number
of Shares That May
Yet Be Purchased
Under The Plans or
Programs
 
 
(in millions)
 
 
 
(in millions)
 
(in millions)
April 30, 2015
 

 
$

 

 
63

May 31, 2015
 

 

 

 
63

June 30, 2015
 

 

 

 
63

Total
 

 
$

 

 
 
 
(a)
In November 1997, our Board of Directors adopted a share repurchase program, which the Board evaluates periodically. In June 2014, the Board renewed our share repurchase program with an authorization to repurchase up to 100 million shares of our common stock in open market purchases or other types of transactions (including prepaid or structured repurchase programs). There is no established expiration date for the program.
(b)
During the three months ended June 30, 2015, we repurchased 0.5 million shares at an average price of $117 per share.

30

Table of Contents

ITEM 6.
EXHIBITS**

The following exhibits are filed in response to Item 601 of Regulation S-K.
3.1

 
Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2

 
Bylaws of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form 8-A/A filed on July 1, 2015)
4.1

 
Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)
4.2

 
Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2001)
4.3

 
Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior Indenture, dated as of November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007)
4.4

 
Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008)
*10.1

 
Amended and Restated UnitedHealth Group Incorporated 2011 Stock Incentive Plan, effective June 1, 2015 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 5, 2015)
  12.1

 
Computation of Ratio of Earnings to Fixed Charges
  31.1

 
Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  32.1

 
Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  101

 
The following materials from UnitedHealth Group Incorporated’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 filed on July 29, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Changes in Shareholders' Equity, (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements.
 ________________
*
 
Denotes management contracts and compensation plans in which certain directors and named executive officers participate and which are being filed pursuant to Item 601(b)(10)(iii)(A) of Regulation S-K.
**
 
Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.



31

Table of Contents

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
UNITEDHEALTH GROUP INCORPORATED
 
/s/    STEPHEN J. HEMSLEY
 
Chief Executive Officer
(principal executive officer)
Dated:
July 29, 2015
Stephen J. Hemsley
 
  
 
 
 
 
/s/    DAVID S. WICHMANN
 
President and Chief Financial Officer
(principal financial officer)
Dated:
July 29, 2015
David S. Wichmann
 
  
 
 
 
 
/S/    ERIC S. RANGEN
 
Senior Vice President and
Chief Accounting Officer
(principal accounting officer)
Dated:
July 29, 2015
Eric S. Rangen
 
  
 


32

Table of Contents

EXHIBIT INDEX**
 
The following exhibits are filed in response to Item 601 of Regulation S-K.
3.1

 
Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2

 
Bylaws of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form 8-A/A filed on July 1, 2015)
4.1

 
Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)
4.2

 
Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2001)
4.3

 
Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior Indenture, dated as of November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007)
4.4

 
Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008)
*10.1

 
Amended and Restated UnitedHealth Group Incorporated 2011 Stock Incentive Plan, effective June 1, 2015 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 5, 2015)
12.1

 
Computation of Ratio of Earnings to Fixed Charges
31.1

 
Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1

 
Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101

 
The following materials from UnitedHealth Group Incorporated’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 filed on July 29, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Changes in Shareholders' Equity, (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements.
 ________________
*
 
Denotes management contracts and compensation plans in which certain directors and named executive officers participate and which are being filed pursuant to Item 601(b)(10)(iii)(A) of Regulation S-K.
**
 
Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.


33